Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2025-12-25 @ 12:53 AM
NCT ID:
NCT07297667
Brief Summary:
This study is being done to answer the following questions:
* Is the new cell therapy, GCAR1, safe to use, and what effects does it have on cancer?
* What is the right dose of the treatment which could be used in future studies?
Detailed Description:
GCAR1 is an autologous chimeric antigen receptor (CAR-T) cell therapy. Autologous means that it is made from a specific person's own white blood cells. These white blood cells are collected from the person and are modified in a laboratory to be able to better find and destroy cancer cells.
We are doing this study because to find out if this approach is better or worse than the usual approach for cancer. The usual approach is defined as care most people get for this type of cancer.
The usual approach for patients who are not in a study is treatment with chemotherapy or other anti-cancer drugs. The drugs chosen will depend on the type of cancer. If there is kidney or breast cancer, radiation therapy may also be used. The study doctor can explain which treatment may be best. These treatments can reduce symptoms and may stop the tumour from growing for a few months or longer.
Study:
NCT07297667
Study Brief:
Protocol Section:
NCT07297667